Duclos Antoine, Chollet François, Pascal Léa, Ormando Hector, Carty Matthew J, Polazzi Stéphanie, Lifante Jean-Christophe
Health Services and Performance Research lab (HeSPeR, EA 7425), Université Claude Bernard Lyon 1, France
Health Data Department, Hospices Civils de Lyon, France.
BMJ. 2020 Nov 4;371:m3840. doi: 10.1136/bmj.m3840.
To determine the effect of introducing prospective monitoring of outcomes using control charts and regular feedback on indicators to surgical teams on major adverse events in patients.
National, parallel, cluster randomised trial embedding a difference-in-differences analysis.
40 surgical departments of hospitals across France.
155 362 adults who underwent digestive tract surgery. 20 of the surgical departments were randomised to prospective monitoring of outcomes using control charts with regular feedback on indicators (intervention group) and 20 to usual care only (control group).
Prospective monitoring of outcomes using control charts, provided in sets quarterly, with regular feedback on indicators (intervention hospitals). To facilitate implementation of the programme, study champion partnerships were established at each site, comprising a surgeon and another member of the surgical team (surgeon, anaesthetist, or nurse), and were trained to conduct team meetings, display posters in operating rooms, maintain a logbook, and devise an improvement plan.
The primary outcome was a composite of major adverse events (inpatient death, intensive care stay, reoperation, and severe complications) within 30 days after surgery. Changes in surgical outcomes were compared before and after implementation of the programme between intervention and control hospitals, with adjustment for patient mix and clustering.
75 047 patients were analysed in the intervention hospitals (37 579 before and 37 468 after programme implementation) versus 80 315 in the control hospitals (41 548 and 38 767). After introduction of the control chart, the absolute risk of a major adverse event was reduced by 0.9% (95% confidence interval 0.4% to 1.4%) in intervention compared with control hospitals, corresponding to 114 patients (70 to 280) who needed to receive the intervention to prevent one major adverse event. A significant decrease in major adverse events (adjusted ratio of odds ratios 0.89, 95% confidence interval 0.83 to 0.96), patient death (0.84, 0.71 to 0.99), and intensive care stay (0.85, 0.76 to 0.94) was found in intervention compared with control hospitals. The same trend was observed for reoperation (0.91, 0.82 to 1.00), whereas severe complications remained unchanged (0.96, 0.87 to 1.07). Among the intervention hospitals, the effect size was proportional to the degree of control chart implementation witnessed. Highly compliant hospitals experienced a more important reduction in major adverse events (0.84, 0.77 to 0.92), patient death (0.78, 0.63 to 0.97), intensive care stay (0.76, 0.67 to 0.87), and reoperation (0.84, 0.74 to 0.96).
The implementation of control charts with feedback on indicators to surgical teams was associated with concomitant reductions in major adverse events in patients. Understanding variations in surgical outcomes and how to provide safe surgery is imperative for improvements.
ClinicalTrials.gov NCT02569450.
确定采用控制图对手术结果进行前瞻性监测并定期向手术团队反馈指标,对患者主要不良事件的影响。
采用差异分析的全国性、平行、整群随机试验。
法国各地40家医院的外科科室。
155362例接受消化道手术的成年人。20个外科科室被随机分配至采用控制图对结果进行前瞻性监测并定期反馈指标(干预组),另外20个科室仅接受常规护理(对照组)。
使用控制图对结果进行前瞻性监测,每季度提供一次,并定期反馈指标(干预医院)。为便于该项目的实施,在每个地点建立了由一名外科医生和手术团队的另一名成员(外科医生、麻醉师或护士)组成的研究支持伙伴关系,并接受培训以组织团队会议、在手术室张贴海报、维护日志以及制定改进计划。
主要结局为术后30天内主要不良事件(住院死亡、重症监护病房停留、再次手术和严重并发症)的综合指标。比较干预医院和对照医院在项目实施前后手术结局的变化,并对患者构成和聚类情况进行调整。
干预医院分析了75047例患者(项目实施前37579例,实施后37468例),对照医院为80315例(41548例和38767例)。引入控制图后,与对照医院相比,干预医院主要不良事件的绝对风险降低了0.9%(95%置信区间0.4%至1.4%),相当于每预防1例主要不良事件,需要114例患者(70至280例)接受干预。与对照医院相比,干预医院的主要不良事件(调整后的比值比为0.89,95%置信区间0.83至0.96)、患者死亡(0.84,0.71至0.99)和重症监护病房停留时间(0.85,0.76至0.94)均显著降低。再次手术也观察到相同趋势(0.91,0.82至1.00),而严重并发症保持不变(0.96,0.87至1.07)。在干预医院中,效应大小与控制图的实施程度成正比。高度合规的医院在主要不良事件(0.84,0.77至0.92)、患者死亡(0.78,0.63至0.97)、重症监护病房停留时间(0.76,0.67至0.87)和再次手术(0.84,0.74至0.96)方面的降低更为显著。
向手术团队实施带有指标反馈的控制图与患者主要不良事件的同时减少相关。了解手术结局的差异以及如何提供安全手术对于改进至关重要。
ClinicalTrials.gov NCT02569450。